Screener
Haemonetics HAE D&A
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
|---|---|---|
| Cash Flows from Operating Activities: | ||
| Net income | $33,010 | $34,031 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 27,111 | 28,758 |
| Amortization of fair value inventory step-up | — | 2,436 |
| Share-based compensation expense | 9,311 | 9,312 |
| Deferred income taxes | 668 | (3,231) |
| Other non-cash operating activities | 2,227 | 1,571 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's D&A?
- Haemonetics (HAE) reported D&A of $27.11M in Q2 2026.
- How has Haemonetics's D&A changed year-over-year?
- Haemonetics's D&A decreased by 5.7% year-over-year, from $28.76M to $27.11M.
- What is the long-term trend for Haemonetics's D&A?
- Over 4 years (2022 to 2026), Haemonetics's D&A has grown at a 16.5% compound annual growth rate (CAGR), from $60.74M to $111.72M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Haemonetics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude